Robert Findling
Child & Adolescent Psychiatry · Cleveland, OHNPI 1174549679
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $84,457 of the $125,230 with a category attached, or 67.4%. It is spread thinly across 20 manufacturers, the largest accounting for just 16.2%. Reporting peaked in 2024 at $30,909 and has fallen 52.7% since, to $14,630 in 2025. Among child & adolescent psychiatry clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $941.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$20K
- Supernus Pharmaceuticals, Inc.$16K
- Merck$13K
- Tris Pharma Inc$11K
- AbbVie$10K
- Alkermes, Inc.$10K
- plus $46K from 14 others
Across 138 payments — averaging $2175.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shire North American Group Inc$73K
- H. Lundbeck A S$56K
- Supernus Pharmaceuticals, Inc.$53K
- AbbVie$41K
- Pfizer$37K
- F. Hoffmann-la Roche AG$25K
- plus $16K from 5 others
What the payments were for
- Consulting fees$84,45767%
- Speaking & faculty fees$29,31923%
- Travel & lodging$6,2755%
- Food & beverage$2,9912%
- Education$2,1882%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 24 | $20,265 |
| Supernus Pharmaceuticals, Inc. | 23 | $15,584 |
| Merck | 12 | $12,796 |
| Tris Pharma Inc | 10 | $10,837 |
| AbbVie | 7 | $10,137 |
| Alkermes, Inc. | 9 | $9,923 |
| Roche Products Limited | 4 | $8,813 |
| E.r. Squibb & Sons, L.L.C. | 5 | $7,075 |
| Sumitomo Pharma Co., Ltd. | 6 | $5,600 |
| Arbor Pharmaceuticals, Inc. | 3 | $5,408 |
| F. Hoffmann-la Roche AG | 5 | $4,524 |
| Shire North American Group Inc | 11 | $4,389 |
| MDD US Operations, LLC | 1 | $2,000 |
| Corium, LLC | 1 | $1,800 |
| Bioxcel Therapeutics, Inc. | 1 | $1,575 |
| Acadia Pharmaceuticals Inc | 2 | $1,250 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $1,200 |
| Pfizer | 5 | $935 |
| Radius Health, Inc. | 1 | $750 |
| Sunovion Pharmaceuticals Inc. | 1 | $369 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$125,230 in reported general payments places this provider in the 95th percentile of 160 child & adolescent psychiatry providers in Ohio.
Other child & adolescent psychiatry in Cleveland
- Andre ProchoroffCleveland$26K
- Nora McNamaraCleveland$3K
- Samareh MoussavandCleveland$3K
- Dean ShandyCleveland$2K
- Rajalla PrewittCleveland$2K
- Diana Sabagh SabaghCleveland$2K
- Mackenzie VarkulaCleveland$709
- Pilar LachhwaniCleveland$563
- Rick BowersMoraine$182K
- Joseph RiemanFremont$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.